BioLineRX (BLRX)

• Market cap: $22.1M
• 1 day: -11.34%
• 5 days: -25.79%
• 1 month: 47.02%
• 3 months: 53.77%
• 6 months: -47.89%
• Year to date: -54.11%
• 1 year: -82.76%
• 5 years: -92.76%
• 10 years: -99.60%
• Sector: Healthcare
• Industry: Biotechnology

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 28

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.15% less ownership

Funds ownership: 0.15% [Q4 2024] → 0% (-0.15%) [Q1 2025]

65% less funds holding

Funds holding: 31 [Q4 2024] → 11 (-20) [Q1 2025]

87% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 23

94% less capital invested

Capital invested by funds: $436K [Q4 2024] → $28K (-$408K) [Q1 2025]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 8

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 156% upside
• Avg. target: $19 305% upside
• High target: $26 454% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Jones Trading Justin Walsh	156% upside $12	Buy Upgraded	30 May 2025
HC Wainwright & Co. Joseph Pantginis	454% upside $26	Buy Reiterated	28 May 2025